Lyell Immunopharma (LYEL) Other financing activities (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Other financing activities data on file, last reported at $26000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other financing activities changed N/A year-over-year to $26000.0; the trailing twelve-month figure through Mar 2026 stood at $391000.0 (down 65.85% YoY), and the FY2025 full-year result was $365000.0, down 70.75% from the prior year.
• Other financing activities declined to $26000.0 in Q1 2026, from $181000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $8.7 million in Q4 2022 to a low of -$3.2 million in Q3 2022.
• A 5-year average of $823000.0 and a median of $182500.0 in 2025 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities slumped 712.1% in 2022 and surged 623.84% in 2024, its largest moves.
• Tracing LYEL's Other financing activities over 5 years: stood at $8.7 million in 2022, then sank by 98.26% to $151000.0 in 2023, then surged by 623.84% to $1.1 million in 2024, then plunged by 83.44% to $181000.0 in 2025, then sank by 85.64% to $26000.0 in 2026.
• Business Quant data shows LYEL's Other financing activities at $26000.0 in Q1 2026, $181000.0 in Q4 2025, and $184000.0 in Q2 2025.